These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33626965)

  • 21. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.
    Burns JE; Stirrup O; Waters L; Dunn D; Gilson R; Pett SL
    HIV Med; 2022 Mar; 23(3):294-300. PubMed ID: 34634168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
    Han WM; Kerr SJ; Avihingsanon A; Boettiger DC
    J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.
    Asundi A; Olson A; Jiang W; Varshney SP; White LF; Sagar M; Lin NH
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):208-215. PubMed ID: 34877881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.
    Wu K; Koethe J; Hulgan T; Brown T; Bares SH; Tassiopoulos K; Lake JE; Leonard M; Samuels DC; Erlandson K; Haas DW
    Pharmacogenet Genomics; 2024 Feb; 34(2):25-32. PubMed ID: 37910437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
    Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
    AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.
    Maman O; Ahmad WA; Perzon O; Mahlab-Guri K; Elbirt D; Elinav H
    BMC Infect Dis; 2024 Feb; 24(1):221. PubMed ID: 38373940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
    Davy-Mendez T; Napravnik S; Zakharova O; Wohl DA; Farel CE; Eron JJ
    AIDS; 2019 Jun; 33(7):1187-1195. PubMed ID: 30870198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
    Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
    Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.
    Levy ME; Griffith C; Ellenberger N; Monroe AK; Castel AD; Rakhmanina N;
    Pediatr Infect Dis J; 2020 May; 39(5):421-428. PubMed ID: 32176183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review.
    Hester EK; Greenlee S; Durham SH
    Ann Pharmacother; 2022 Feb; ():10600280211073321. PubMed ID: 35130714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.
    Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD;
    AIDS; 2022 Feb; 36(2):277-286. PubMed ID: 34934020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.
    Verburgh ML; Wit FWNM; Boyd A; Verboeket SO; Reiss P; van der Valk M
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac291. PubMed ID: 35873291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
    Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.
    Palella FJ; Hou Q; Li J; Mahnken J; Carlson KJ; Durham M; Ward D; Fuhrer J; Tedaldi E; Novak R; Buchacz K
    J Acquir Immune Defic Syndr; 2023 Jan; 92(1):67-75. PubMed ID: 36150045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight.
    McMahon C; Trevaskis JL; Carter C; Holsapple K; White K; Das M; Collins S; Martin H; Burns-Naas LA
    PLoS One; 2020; 15(2):e0229617. PubMed ID: 32109250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
    Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
    Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
    Rein SM; Lodi S; Logan RW; Touloumi G; Antoniadou A; Wittkop L; Bonnet F; van Sighem A; van der Valk M; Reiss P; Klein MB; Young J; Jarrin I; d'Arminio Monforte A; Tavelli A; Meyer L; Tran L; Gill MJ; Lang R; Surial B; Haas AD; Justice AC; Rentsch CT; Phillips A; Sabin CA; Miro JM; Trickey A; Ingle SM; Sterne JAC; Hernán MA;
    Lancet HIV; 2023 Nov; 10(11):e723-e732. PubMed ID: 37923486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.